Fighting cancer with next generation oncolytic immunotherapy in ovarian, head & neck, and lung cancers (Immune Checkpoint Response Enabling Adenovirus Technology )

TILT Biotherapeutics is a clinical-stage biotechnology company developing novel gene therapies for cancer. TILTs lead asset, TILT-123, is an oncolytic adenovirus armed with two human cytokines: TNF alpha and IL-2. TILT-123 is now in several Phase 1 clinical trials in Europe, the U.S. and China. The asset has been tailored to immunologically heat up cold tumors.

Multiple antitumor mechanisms are activated: direct immunogenic killing of cancer cells while sparing healthy cells, release of tumor epitopes, production of cytokines locally at the tumor, and stimulation of patients own immune system to attack cancer.

This approach provides the tumor with presence of immune cells: a prerequisite for immune checkpoint inhibitors (ICIs) to work and benefit patients.

The project objective is to provide a curative treatment option to patients with refractory cancer, such as the ovarian, head and neck, or lung cancer and secure a global pharmaceutical customer to take TILT-123 to the market.